The combination of chemotherapeutic agents with monoclonal antibodies against cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) attracted attention for cancer treatment, however high production costs, immunogenicity, and poor tumor penetration limit their use [120]. This evidence concerns the gene CD274 and cancer.